Researchers at the University of Cambridge and the spinout firm DIOSynVax have completed the first human trial of a coronavirus vaccine featuring an antigen designed entirely by artificial intelligence. The Phase 1 study, published in the Journal of Infection, confirmed that the candidate, pEVAC-PS, is safe and well-tolerated in 39 healthy participants. While the vaccine produced cross-reactive immune responses against various SARS-related coronaviruses, researchers noted that neutralising activity remained modest, signaling a need for further clinical development.
How AI design differs from traditional vaccines
Traditional vaccine development relies on identifying existing viral strains and adapting them for human immune response. In contrast, the pEVAC-PS candidate uses an AI-designed “super-antigen.” According to the University of Cambridge, this digital approach identifies conserved genetic features across the entire Sarbeco family of viruses. By focusing on these fixed targets, the vaccine aims to provide protection against both known and future, mutated coronaviruses.
The pEVAC-PS vaccine is delivered via a needle-free micro-fluid jet. This technology uses a high-pressure stream to deliver DNA directly into the skin, bypassing the need for traditional hypodermic needles.
What the Phase 1 data reveals
The trial, conducted at NIHR facilities in Southampton and Cambridge, enrolled healthy volunteers aged 18 to 50. Data from the Journal of Infection reports that the vaccine successfully triggered an immune response across SARS-CoV-2, SARS, and related bat coronaviruses. However, the study authors acknowledged a limitation: the immune response was modest. Unlike conventional vaccines that may produce highly specific neutralising antibodies, this AI-designed candidate prioritizes breadth over depth, creating a “future-proof” defense that remains in early stages of verification.
The shift to proactive immunization
Professor Jonathan Heeney, the lead researcher, describes this technology as a transition from “reactive” to “future-proof” vaccine development. This approach mirrors shifts seen in other computational biology fields, where machine learning predicts protein folding or viral evolution before a pathogen jumps to humans. While the current results show promise, the scientific community is watching to see how Phase 2 trials will optimize the dosage to achieve more robust neutralising activity, according to coverage by AFP.
Pro tips for understanding vaccine trials
- Dose-escalation: Early trials often start with small, safe doses to monitor for adverse reactions before increasing the amount.
- Cross-reactivity: This refers to an immune system’s ability to recognize a similar pathogen to one it has previously encountered or been vaccinated against.
- Phase 1 Goals: The primary objective here is safety and tolerability, not necessarily full efficacy or long-term immunity.
Frequently Asked Questions
Was the vaccine effective against SARS-CoV-2?
The trial found the vaccine was safe and produced cross-reactive responses to the virus, though current results indicate the neutralising activity was modest rather than broad or robust.
What is a “super-antigen”?
In this context, it refers to an antigen designed by AI to target conserved features common across an entire family of coronaviruses, rather than a single specific strain.
What happens next for the pEVAC-PS project?
Researchers have confirmed that a Phase 2 study is being planned to further evaluate the vaccine’s performance and immune response in larger groups.
Stay informed on the latest breakthroughs in biotechnology and medical research. Subscribe to our newsletter for weekly updates on AI-driven health innovations.